Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Health Yuan enters the analgesia track, Nav1.8 inhibitor expands the synergistic boundary of chronic disease ecology

Time Posted:2025-03-26 09:39

Driven by the trend of innovative drugs accelerating towards mechanism upgrades and precise expansion of indications, HealthGen Pharma has begun to lay out a diversified innovation field beyond its main line of respiratory disease treatment. The company's R&D project targeting Nav1.8 sodium channel inhibitors for analgesia marks a significant extension in its chronic disease treatment chain, and also reflects its path choice of continuously deepening its multi-pipeline synergy strategy.

Healthy Yuan TSLP monoclonal antibody: Breaking through the bottleneck of COPD treatment and promoting a new era of precision medicine

Time Posted:2025-03-19 10:24

Chronic obstructive pulmonary disease (COPD) is a prevalent chronic disease worldwide, significantly impacting patients' quality of life and placing a heavy burden on healthcare systems. Statistics indicate that there are over 300 million COPD patients globally, with over 100 million in China. However, due to low early diagnosis rates, many patients are diagnosed at an irreversible stage. With the development of precision medicine, innovative biologics are becoming a new direction in COPD treatment. HealthyGen Pharmaceuticals Group (600380.SH) is accelerating the research and development of TSLP monoclonal antibody and IL-4R monoclonal antibody, hoping to provide more effective treatment options for patients through scientific innovation and to promote the upgrading of COPD treatment methods.

Health Yuan Innovation contributes to a 'Healthy China' initiative, safeguarding the respiratory health of hundreds of millions.

Time Posted:2025-03-11 15:30

Against the backdrop of intensifying global public health challenges, China is accelerating the "Healthy China 2030" strategy to improve the overall health of its population and optimize its chronic disease management system. The agenda of the National People's Congress and the Chinese People's Political Consultative Conference in 2025 also focused on chronic disease prevention and control, optimization of primary-level medical resources, and the construction of the public health system, providing policy support for the innovative development of the pharmaceutical industry. As a leading domestic enterprise in the respiratory field, HealthGen Biotech Group is leveraging technological innovation to comprehensively develop a respiratory disease prevention and control system, contributing to national public health construction, and promoting the leading position of China's pharmaceutical industry in global competition.

Health Yuan was included in S&P Global's Sustainability Yearbook 2025 (Global Edition) for its innovation-driven sustainable development.

Time Posted:2025-02-14 10:40

Recently, HealthGen Biotech Group was successfully included in S&P Global's Sustainability Yearbook 2025 (Global Edition) due to its outstanding performance in Environmental, Social, and Governance (ESG). This honor not only demonstrates HealthGen's continuous efforts and remarkable achievements in sustainable development but also signifies the company's leading position in ESG practices within the global pharmaceutical industry.

Influenza is coming! Deepseek reveals the secrets of Health Yuan's "Mapassive"

Time Posted:2025-02-13 08:40

Recently, influenza A virus has resurged and spread rapidly across the country, seriously affecting people's work and life. Common symptoms after infection include high fever, cough, and fatigue. Some patients even develop serious complications, putting considerable pressure on the medical system. Experts urge the public to be vigilant and seek medical attention early.

Responsibility in heart, action in deed | Healthy Element firmly practices social responsibility to promote the comprehensive revitalization of rural areas

Time Posted:2025-01-26 17:00

In today's rapidly developing society, enterprises are not only the backbone of the economy, but also important players in fulfilling social responsibilities and promoting social progress. Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Joincare"), as a large comprehensive pharmaceutical group in the pharmaceutical industry, has not only achieved remarkable results in R&D innovation and new drug pipelines, but also made significant contributions in social responsibility.

Ranked among the top 5% in the industry, Healthy Yuan's S&P Global ESG rating has once again achieved a high score and been included in the list.

Time Posted:2025-01-21 14:00

Recently, the results of the S&P Global Sustainability Assessment were released. Health Yuan (600380.SH) stood out with its excellent Environmental, Social, and Governance (ESG) performance. In the 2024 S&P Global Corporate Sustainability Assessment, it achieved a score of 69, surpassing 95% of its peer companies and ranking third among participating pharmaceutical companies in China.

The Jiankangyuan PREP target COPD innovative drug project has entered a phase I bridging healthy subject study.

Time Posted:2025-01-13 14:52

Recently, HealthGen's PREP-targeted COPD innovative drug project has achieved a key milestone. This drug is expected to become China's first innovative mechanism oral COPD drug and has officially entered the "Phase 1 bridging healthy subject study". This marks a significant step in the project's transition from research and development to clinical application, laying a solid foundation for the future launch of the new drug.

< 1...345...55 >